Alternatives to Nivestym If You Can't Fill Your Prescription

If you've been prescribed Nivestym (filgrastim-aafi) and you're struggling to fill it — whether due to availability, insurance issues, or cost — there's good news: several alternative medications work through the same mechanism and may be more accessible to you right now.

This guide covers each Nivestym alternative, how they compare, and important things to discuss with your doctor before switching.

What Class of Drug Is Nivestym?

Nivestym belongs to the granulocyte colony-stimulating factor (G-CSF) class. These medications stimulate the bone marrow to produce more neutrophils — infection-fighting white blood cells. They are critical in oncology to prevent dangerous infections after chemotherapy.

Nivestym is specifically a biosimilar to Neupogen (filgrastim), meaning it has been FDA-approved as highly similar to Neupogen with no clinically meaningful differences in safety or effectiveness. Several other filgrastim biosimilars have also been approved, and all offer the same basic therapeutic benefit.

Alternative 1: Zarxio (filgrastim-sndz) — The First FDA-Approved Filgrastim Biosimilar

Zarxio was approved by the FDA in 2015 as the first-ever biosimilar approved in the United States. Manufactured by Sandoz, it is approved for the same indications as Neupogen. Zarxio is widely available and is one of the most commonly prescribed filgrastim products in oncology settings.

A key difference: Zarxio prefilled syringes can be stored at room temperature for up to 4 days (compared to 24 hours for Nivestym and Neupogen), giving it slightly more flexibility for patients.

Best for: Patients on standard myelosuppressive chemotherapy, AML induction/consolidation, bone marrow transplant support, PBPC mobilization, and severe chronic neutropenia.

Alternative 2: Releuko (filgrastim-ayow) — A Newer Biosimilar Option

Releuko (filgrastim-ayow) was FDA-approved in February 2022. It is biosimilar to Neupogen and approved for most of the same indications — with one important exception: Releuko is not FDA-approved for peripheral blood progenitor cell (PBPC) mobilization (stem cell transplant prep). If your indication is stem cell mobilization, Zarxio or Nivestym would be preferred.

Best for: Chemotherapy-induced neutropenia, AML, and BMT support (not PBPC mobilization).

Alternative 3: Nypozi (filgrastim-txid) — The Newest Biosimilar

Nypozi (filgrastim-txid) received FDA approval in June 2024, making it the newest filgrastim biosimilar on the U.S. market. It is approved for the same broad indications as Neupogen. As a newer entrant, it may be available at pharmacies that have it as a preferred formulary option.

Best for: Same broad indications as Neupogen including HARS (acute radiation syndrome), chemotherapy, AML, BMT, SCN, and PBPC mobilization.

Alternative 4: Neupogen (filgrastim) — The Original Reference Biologic

Neupogen is the original filgrastim product manufactured by Amgen and approved by the FDA in 1991. It has the broadest indication set of all filgrastim products — it is the only one approved for the hematopoietic syndrome of acute radiation syndrome (HARS) along with Zarxio, Releuko, and Nypozi. Nivestym is NOT approved for HARS.

Neupogen is typically more expensive than its biosimilars, so if cost is a concern, one of the biosimilars above may be a better choice.

Alternative 5: Granix (tbo-filgrastim) — A Similar G-CSF (Not a Biosimilar)

Granix (tbo-filgrastim) from Teva is a G-CSF product with a similar mechanism to Nivestym but it is technically not a biosimilar — it was approved under a different regulatory pathway. It is FDA-approved for chemotherapy-related neutropenia but not for all the same indications as Neupogen. It's worth mentioning as a potential option your doctor may consider.

Alternative 6: Neulasta (pegfilgrastim) — The Long-Acting Option

Neulasta (pegfilgrastim) is a pegylated form of filgrastim — it stays in the body much longer, so it's given just once per chemotherapy cycle (instead of daily injections like Nivestym). It has become a popular alternative because of the convenience of one injection instead of daily dosing.

However, Neulasta is not appropriate for all indications. It is not approved for bone marrow transplantation, AML chemotherapy, or severe chronic neutropenia — situations where Nivestym and other daily filgrastims are preferred. Discuss with your oncologist whether the switch makes clinical sense.

Side-by-Side Comparison

Here's a quick overview of the alternatives:

• Zarxio — Most widely available biosimilar; approved for nearly all the same uses as Nivestym
• Releuko — Biosimilar approved 2022; not approved for PBPC mobilization
• Nypozi — Newest biosimilar (2024); broadest indication set including HARS
• Neupogen — Original biologic; broadest indications; typically more expensive
• Granix — Similar mechanism, not a true biosimilar; limited indications
• Neulasta — Once-per-cycle dosing; not for BMT, AML, or SCN

Always Talk to Your Doctor Before Switching

Do not switch G-CSF medications without consulting your oncologist. The right choice depends on your specific cancer type, treatment regimen, and insurance coverage. Your doctor can rewrite the prescription quickly if a switch is medically appropriate.

Still Can't Find Nivestym?

If you haven't tried medfinder yet, it's a service that calls pharmacies near you to check stock. See our guide on how to find Nivestym in stock near you for a step-by-step approach.